secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001790340-25-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named
--------------------------------------------------------------------------------

- Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.
- Cash $35.9M as of March 31, 2025; runway extended into 2026.
- Positive IMM-1-104 data: 13-month monotherapy PFS in third-line pancreatic cancer; complete response in first-line combo with chemo.
- Named Dr. Igor Matushansky as CMO; signed clinical supply agreement with Regeneron for Libtayo combo in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/0001790340-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/imrx-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer